New eyedrop aims to halt progressive eye disease
NCT ID NCT07388069
First seen Feb 04, 2026 · Last updated May 16, 2026 · Updated 27 times
Summary
This early-stage trial tests TN-001 eyedrops in 20 adults with progressive keratoconus, a condition that thins and bulges the cornea. Participants use the drops twice daily for 3-6 weeks. The main goals are to check safety and see if the drops can stop the disease from advancing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KERATOCONUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ophthalmic Trials Australia
Brisbane, Queensland, 4005, Australia
Conditions
Explore the condition pages connected to this study.